BerandaICPT • BMV
add
Intercept Pharmaceuticals Ord Shs
Tutup sebelumnya
$329,00
Rentang tahun
$329,00 - $329,00
Kapitalisasi pasar
794,36 jt USD
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2023info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 88,79 jt | 14,44% |
Biaya operasional | 86,95 jt | -0,41% |
Laba bersih | -2,79 jt | -101,04% |
Margin laba bersih | -3,14 | -100,91% |
Penghasilan per saham | 0,08 | -99,20% |
EBITDA | 1,74 jt | 117,27% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2023info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 322,71 jt | -34,25% |
Total aset | 393,16 jt | -29,72% |
Total liabilitas | 321,32 jt | -28,87% |
Total ekuitas | 71,84 jt | — |
Saham yang beredar | 41,83 jt | — |
Harga terhadap nilai buku | 191,28 | — |
Tingkat pengembalian aset | 0,93% | — |
Tingkat pengembalian modal | 1,18% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2023info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -2,79 jt | -101,04% |
Kas dari operasi | 16,69 jt | 200,59% |
Kas dari investasi | 59,77 jt | -81,97% |
Kas dari pembiayaan | -110,00 jt | 57,27% |
Perubahan kas bersih | -33,70 jt | -163,39% |
Arus kas bebas | 16,70 jt | 211,23% |
Tentang
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
CEO
Didirikan
2002
Situs
Karyawan
341
